National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi®) is indicated the treatment of chronic hepatitis C virus (HCV) infection in adults – pangenotypic i.e. all genotypes (GT1, 2, 3, 4, 5 and 6).

 

NCPE Rapid Review Process Completed
Rapid review received 19/09/2017
Rapid review completed 15/11/2017
Rapid Review outcome Full pharmacoeconomic assessment not recommended